Compare COFS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | COFS | CTNM |
|---|---|---|
| Founded | 1898 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.2M | 416.1M |
| IPO Year | N/A | 2024 |
| Metric | COFS | CTNM |
|---|---|---|
| Price | $29.45 | $11.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $39.00 | $20.00 |
| AVG Volume (30 Days) | 158.5K | ★ 264.6K |
| Earning Date | 01-21-2026 | 10-30-2025 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $127,930,000.00 | N/A |
| Revenue This Year | $82.06 | N/A |
| Revenue Next Year | $8.49 | N/A |
| P/E Ratio | $17.15 | ★ N/A |
| Revenue Growth | ★ 45.55 | N/A |
| 52 Week Low | $24.89 | $3.35 |
| 52 Week High | $36.26 | $15.25 |
| Indicator | COFS | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 46.77 |
| Support Level | $29.04 | $11.66 |
| Resistance Level | $31.09 | $12.80 |
| Average True Range (ATR) | 0.91 | 0.69 |
| MACD | -0.33 | -0.07 |
| Stochastic Oscillator | 10.62 | 6.55 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.